share_log

Chardan Capital Maintains Buy on ProQR Therapeutics, Raises Price Target to $2.5

Moomoo 24/7 ·  Mar 14 06:27

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $2 to $2.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment